Skip to Content

Teduglutide Dosage

Applies to the following strength(s): 5 mg

The information at is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for Short Bowel Syndrome

0.05 mg/kg administered by subcutaneous injection once a day.

Use: Treatment of patients with Short Bowel Syndrome who are dependent on parenteral support.

Renal Dose Adjustments

-Mild Renal Dysfunction: Data not available.
-Moderate Renal Dysfunction: Reduce the dose by 50%.
-Severe Renal Dysfunction (CrCl less than 50 mL/min) and ESRD: Reduce the dose by 50%.

Liver Dose Adjustments

-Mild Liver Dysfunction: No adjustment recommended.
-Moderate Liver Dysfunction: No adjustment recommended.
-Severe Liver Dysfunction: Data not available.


US REMS: The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for this drug. It includes a communication plan and elements to assure safe use. For additional information:

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:
-Alternation of injection sites is recommended, and can include the thighs, arms, and abdomen quadrants.
-A missed dose should be taken as soon as possible on that day. Do not take 2 doses on the same day.
-Do not administer this drug intravenously or intramuscularly.

Storage requirements:
-Consult the manufacturer product information.

Reconstitution/preparation techniques:
-Consult the manufacturer product information.

-Discontinuation of treatment should be managed carefully as it may result in fluid and electrolyte imbalance.
-Administration of this drug may trigger the development of antibodies, which is consistent with the potentially immunogenic properties of medicinal products containing peptides. Antibody formation appears to have no impact on short term (up to 2.5 years) efficacy and safety, although the long-term impact is unknown.

-Cardiovascular: Fluid overload, electrolyte status
-Gastrointestinal: Small bowel and pancreas function
-Hepatic: Gallbladder and biliary tract function; laboratory assessments of bilirubin, alkaline phosphatase, lipase, and amylase (within 6 months prior to treatment initiation, and every 6 months thereafter; further diagnostic workup recommended if clinically meaningful elevation is seen)
-Oncologic: Entire colon imaging with removal of polyps (within 6 months prior to starting treatment, and at the end of 1 year of treatment; no polyp found: colon imaging at least every 5 years; if polyp found: adhere to current polyp follow-up guidelines)

Patient advice:
-This drug may cause fainting, which could impact your ability to drive and use machines.